Health CarePharmaceuticals & Biotechnology
  • Price (GBX)345.50
  • Today's Change-10.50 / -2.95%
  • Shares traded41.17k
  • 1 Year change-6.11%
  • Beta0.8189
Data delayed at least 20 minutes, as of May 13 2021 13:49 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in all activities related to oncology and immunology including sales, marketing, manufacturing and research and development with respect to drugs and drug candidates. The Other Ventures segment is involved in the other Company’s businesses, including manufacturing or purchase and distribution of pharmaceutical products and other consumer health products as well as provision of services, which are the provision of sales, distribution and marketing services to pharmaceutical manufacturers.

  • Revenue in GBP (TTM)162.24m
  • Net income in GBP-89.47m
  • Incorporated2000
  • Employees1.28k
  • Location
    HUTCHMED (China) Ltd22Nd Floor Hutchison House10 Harcourt Road 00000Hong KongHKG
  • Phone+852 21281188
  • Fax+852 21281778
  • Websitehttps://www.hutch-med.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Silence Therapeutics plc5.48m-32.55m548.91m65.00--56.46--100.18-0.3963-0.39630.0670.10870.083--0.373984,292.30-49.30-29.90-67.23-33.8010.42---594.03-1,238.26---184.780.0363--2,145.49---66.21---9.57--
Ergomed PLC86.39m9.68m582.61m775.0062.2911.0540.116.740.19180.19181.711.081.16--4.08--12.960.609319.380.837745.9039.9311.210.5741--15.880.0881--26.5723.4173.8644.2211.91--
Avacta Group Plc3.64m-18.89m681.71m119.00--10.97--187.49-0.0824-0.08240.01610.24510.07597.201.46---39.41---41.92--59.98---519.55--14.02-72.420.0319--------------
Vectura Group PLC190.60m122.40m709.97m500.005.901.304.133.720.20160.20160.33390.91350.31853.161.57381,200.0020.46--23.37--53.20--64.22--
Oxford BioMedica plc87.73m-6.25m839.03m673.00--7.43233.459.56-0.0817-0.08171.101.370.57188.782.51130,353.60-4.07-8.50-5.54-11.4152.5254.07-7.12-14.241.93-2.850.1094--36.9540.7061.13---4.39--
Puretech Health PLC8.37m4.26m1.04bn66.00562.522.17129.82123.680.00640.00640.02891.670.0122--5.19126,887.600.47315.350.55547.07----38.82290.68----0.10490.0020.00-0.1017-98.58--3.31--
Indivior PLC479.65m67.61m1.09bn819.0017.669.2913.642.270.08380.08380.60050.15940.43161.293.96585,647.606.085.1810.5412.0783.9887.5514.098.001.7912.330.63230.00-17.58-8.59-210.45---33.60--
Udg Healthcare PLC887.39m60.16m2.58bn9.00k42.923.5021.662.900.23820.25053.512.920.706230.993.4398,599.234.793.605.924.5632.5629.496.784.521.8115.530.268167.22-1.493.9753.8814.30-12.546.18
HUTCHMED (China) Ltd162.24m-89.47m2.67bn1.28k--7.57--16.44-0.1278-0.12780.23250.47340.383410.485.00126,747.50-19.43-12.38-26.93-16.8117.3125.31-50.67-27.073.23--0.0644--11.275.05-18.59--42.57--
Genus plc566.40m48.30m3.07bn2.97k63.796.1633.295.420.73680.73688.647.630.6823--5.71190,771.305.673.666.634.20--37.018.325.991.58--0.222357.1812.886.71419.230.29919.068.34
Abcam Plc269.30m-1.90m3.26bn1.50k--5.17105.7912.10-0.0121-0.01211.252.780.37271.956.63179,533.30-0.26299.33-0.306110.6170.0069.98-0.705517.034.7913.210.156749.230.038512.54-72.35-19.6836.70-15.44
Data as of May 13 2021. Currency figures normalised to HUTCHMED (China) Ltd's reporting currency: UK Pound GBX

Institutional shareholders

4.53%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 31 Mar 202112.67m1.70%
Norges Bank Investment Managementas of 31 Dec 202010.25m1.38%
Slater Investments Ltd.as of 30 Jun 20203.66m0.49%
Capital International SARLas of 31 Dec 20202.31m0.31%
M&G Investment Management Ltd.as of 30 Nov 20202.08m0.28%
APG Asset Management NVas of 31 Dec 2020972.93k0.13%
FIL Investment Management (Singapore) Ltd.as of 31 Dec 2020784.10k0.11%
Standard Life Investments Ltd.as of 31 Jan 2021490.10k0.07%
T. Rowe Price International Ltd.as of 31 Dec 2020376.91k0.05%
Capital Research & Management Co. (International Investors)as of 31 Dec 2020132.00k0.02%
More ▼
Data from 30 Jun 2020 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.